ARGENT BIOPHARMA LTD - MGCLF STOCK NEWS

MGC Pharmaceuticals Ltd. has announced that its investigational medicinal product, CannEpil®, is now available to patients in the UK through Named Patient Request. This decision follows the success of Epidiolex, which generated $296 million in sales in 2019, highlighting the potential market for CannEpil® in treating refractory epilepsy. CannEpil®, a high-CBD and low-THC formulation, is currently in clinical development and has already been prescribed to hundreds of patients in Australia and the Republic of Ireland. The company aims to evaluate the safety and efficacy of CannEpil® through data collected from ongoing patient use, supporting future marketing authorization submissions. This expansion into the UK market represents a significant step for MGC Pharma and offers new treatment options for patients with unmet medical needs.

MGC Pharmaceuticals Ltd. (LSE: MXC, OTC: MGCLF) announced that its product ArtemiC™ is now listed as an OTC drug in the US, according to the FDA National Drug Code (NDC) Database. This milestone, facilitated by US partner AMCPharma USA, allows ArtemiC™ to enter US Pharmacy Benefit Management (PBM) networks by April 2023. AMC has placed a US$2 million order, with deliveries scheduled for Q3 and Q4 2023. ArtemiC™, which has shown effectiveness in treating moderate COVID-19 and chronic inflammatory diseases, was developed with Grat Bio® SNEDD technology, ensuring high bioavailability and safety.

MGC Pharmaceuticals Ltd. (OTC: MGCLF) has signed an exclusive distribution agreement with Sciensus Rare to distribute its products, CannEpil® and CogniCann®, in key European markets and the UK. This partnership aims to enhance access to CannEpil®, for drug-resistant epilepsy, and CogniCann®, for dementia and Alzheimer's patients. The agreement covers several countries including Denmark, France, Italy, Spain, Luxembourg, and the UK for an initial four years. MGC Pharma remains responsible for market authorization, while Sciensus Rare handles early access program applications.